PCOS Just Got a New Name — And It’s Long Overdue

If you’ve been diagnosed with polycystic ovary syndrome — or have spent years suspecting you might have it — you may have seen the news out of May 2026: PCOS is no longer called PCOS.

The condition now has an official new name: polyendocrine metabolic ovarian syndrome, or PMOS.

This wasn’t a casual rebrand. It was the result of 14 years of global collaboration involving more than 22,000 doctors, researchers, patients, and advocates across 56 organizations — including the Endocrine Society — and it was formally published in The Lancet. The name change reflects something that precision medicine practitioners have known for years: PCOS was never really about cysts, and it was never just about ovaries. And the way we named it has been quietly doing women a disservice for decades.

Why the Old Name Was the Problem

Here’s what most women are told when they receive a PCOS diagnosis: you have polycystic ovaries, your hormones are off, and here are some birth control pills.

End of conversation.

The name “polycystic ovary syndrome” pointed fingers directly at the ovaries and implied the central issue was cysts. But as Dr. Melanie Cree, a pediatric endocrinology expert at the University of Colorado Anschutz and one of the authors of the Lancet paper, put it plainly: “There’s no cysts in the ovary, so it’s very confusing.”

What actually drives this condition is a systemic disruption of the endocrine system — the body’s entire hormonal communication network. That disruption doesn’t just affect the ovaries. It affects metabolism, insulin sensitivity, weight regulation, cardiovascular health, mental health, skin, sleep, and fertility. The research has shown connections to sleep apnea, depression, anxiety, and body dysmorphia. This is a full-body, multi-system hormonal condition.

The new name — polyendocrine metabolic ovarian syndrome — finally says that out loud. The “polyendocrine” prefix reflects that this is a condition of the broader hormone system, not a localized ovarian quirk. The addition of “metabolic” acknowledges what clinicians who actually pay attention have known for years: insulin resistance and metabolic dysfunction are often at the very core of what’s happening.

After more than 86% of surveyed patients and 71% of healthcare professionals supported adopting an accurate, symptom-based name, the decision was unanimous. Fourteen years in the making. One letter changed. Everything it means, finally shifted.

Why This Matters Beyond Semantics

You might be thinking: it’s just a name. Does it really change anything?

Yes. It changes everything — because the name shapes the diagnosis, and the diagnosis shapes the treatment.

When providers think of this as an ovarian cyst problem, they treat the ovaries. When they think of it as a hormonal and metabolic disorder, they treat the whole system. Those are fundamentally different approaches with fundamentally different outcomes for patients.

For decades, the standard playbook for PCOS has been oral contraceptives to regulate periods and metformin to address insulin resistance. And for many women, that’s where the conversation has ended — year after year, the same two tools, regardless of how much the science has evolved.

The name change signals, loudly, that this approach is no longer sufficient. As the Endocrine Society stated, the old name contributed directly to “missed diagnoses and inadequate treatment.” That’s an indictment from the very body responsible for setting the standard of care.

At Precision Health, I’ve been pushing back against that playbook for years. Not because I’m contrarian — but because the research has been pointing in a different direction, and my patients deserve care that reflects what we actually know.

The Treatment Conversation We Should Be Having

Here’s where it gets interesting — and where modern medicine is finally catching up.

Because PMOS is fundamentally a hormonal and metabolic condition, the most promising emerging therapies are ones that address it on exactly those terms: peptide-based therapies and targeted hormone optimization.

A 2024 study published in Nature Communications examined GLP-1-based multi-agonist therapies — the same class of peptides that underpin medications like semaglutide and tirzepatide — in PCOS models. The results were striking. These therapies demonstrated superior efficacy compared to metformin in improving both the metabolic and reproductive features of the condition. Hormonal markers improved. Metabolic function improved. The outcomes went beyond what the standard pharmacological approach had been able to achieve.

A September 2025 scoping review published in Cureus looked at GLP-1 receptor agonists — including semaglutide, tirzepatide, and the emerging triple agonist retatrutide — across the available literature on PCOS. The conclusion: all three classes showed significant improvements in weight loss and insulin sensitivity compared to traditional management with metformin and oral contraceptives.

This matters enormously, because insulin resistance isn’t a side effect of PMOS — for many women, it’s a central driver of everything else. When you address insulin resistance effectively, the hormonal cascade often begins to normalize downstream: androgen levels improve, cycles regularize, inflammation decreases. You’re not just managing symptoms. You’re addressing root cause.

What Hormone Optimization Actually Looks Like for PMOS

One of the most important shifts in how I approach PMOS is understanding that it’s not a one-size-fits-all diagnosis. PMOS presents differently in every woman. Some carry weight easily and struggle with insulin dysregulation. Others are lean but hyperandrogenic. Some experience severe mood disruption and fatigue as the dominant complaint. Others are primarily concerned with fertility.

The old approach tried to give every woman the same answer. The precision medicine approach asks: what is actually driving your specific presentation, and what tools do we have to address it at that level?

Here’s how that looks in practice:

Comprehensive hormonal mapping. I don’t just look at estrogen and progesterone. I evaluate sex hormone binding globalin (SHB6), androgens (testosterone, DHEA-S), insulin and fasting glucose, LH/FSH ratios, cortisol patterns, thyroid function, and inflammatory markers. PMOS interacts with all of these systems, and treating it without that full picture is guesswork.

Targeted hormone balancing. For women whose androgen excess is driving symptoms — acne, unwanted hair growth, hair thinning — there are approaches beyond masking with oral contraceptives. Optimizing progesterone, addressing cortisol dysregulation, and in some cases using targeted anti-androgen support can directly address the hormonal imbalance rather than just suppressing the cycle.

Peptide and GLP-1-based therapies. For patients where insulin resistance and weight are significant factors — which is the majority — peptide-based approaches have become one of the most powerful tools in my toolkit. They address the metabolic dysfunction that drives the hormonal dysfunction, and the results I see in my patients reflect exactly what the research is now confirming: improvements in weight, insulin sensitivity, cycle regularity, and overall energy that the old standard of care rarely achieved.

Lifestyle architecture. This isn’t a throwaway mention — it’s foundational. Diet composition, sleep quality, stress management, and exercise type (resistance training in particular has a meaningful impact on insulin sensitivity in PMOS) are not optional add-ons. They are core to any treatment plan I build, because they either amplify or undermine everything else we do.

What I Want My PMOS Patients to Hear

If you’ve been carrying a PCOS diagnosis for years and feel like you’ve never quite gotten answers — you’re not imagining it. The medical system named this condition in a way that obscured its true nature, and treatment has lagged as a result.

The renaming of PCOS to PMOS is more than symbolic. It is a formal acknowledgment, from the highest levels of international medicine, that this condition is a complex hormonal and metabolic disorder that demands a more sophisticated approach. The good news is that the research is now pointing clearly toward therapies — including peptide-based and hormone optimization protocols — that can address this condition at a mechanistic level, not just paper over symptoms.

That’s the kind of care I built Precision Health to deliver.

If you’ve been told your labs are “normal,” or that birth control and metformin are your only options, or that your symptoms are just something you have to manage — I’d like to have a different conversation with you.

At Precision Health in Castle Rock, we specialize in hormone optimization, peptide therapy, medical weight loss, healthy aging and precision-based approaches to complex hormonal conditions like PMOS. Visit precisionhealthcr.com/appointment to schedule a consultation with Jill. Serving the South Denver, Castle Pines, Castle Rock, Franktown, Monument and North Colorado Springs communities

Sources

Teede HJ et al., “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process,” The Lancet, May 12, 2026.

Endocrine Society press release, May 2026.

Hudanich M et al., “The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review,” Cureus, September 2025.

“Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy,” Nature Communications, October 2024.